J. Barrett
1100_Barrett
Approaching the In Silico Child
B. Bernhard
B_Bernhard_SV_28.02.06
Can Healthcare Systems Afford Targeted Medicines?
H. Fuder
H._Fuder_IV_02.03.06_01
Gaps Between Biomarkers and Surrogate Endpoints: CNS
R. Krishna
Krishna_SII_28.02.06_01
Approaches to First-In-Man and Beyond: Early Evidence of Target Engagement with Biomarkers and Innovative Clinical Trial Designs.
J. Lesko
1500_Lesko
Tools to Reduce Phase III Trial Failures.
J. Lütz
J._L_tz_SVII_06.03.06_01
Perspective of the German Medicines Agency (BfArM). BfArM after reorganisation of the structure.
B. Meibohm
B._Meibohm_SIII_28.02.06
Interplay between Drug Metabolizing Enzymes
J. Schentag
J._Schentag_SIV_01.03.06_01
The Gap Between Biomarkers and Surrogate Endpoints in the Development of Anti-Infectives.
B. Schug
B._Schug_WS_C_09.03.06
Drug Interaction Studies
T. Sudhop
EU-IMPD_02
What is required for first into man? The EU IMPD.
S. Throm
Throm_SVII_01.03.06_01
Innovation or Stagnation – Perspective of Pharmaceutical Industry.
G. Wensing
1200_Wensing
From Preclinical Data to Proof of Concept – Strategies for First to Man Studies.
M. Zühlsdorf
1630_Z_hlsdorf
The gap between biomarkers and surrogate endpoints Oncology